PPT-In The Name Of God Dyslipidemia

Lipid management in Diabetes DrZahra davoudi Endocrinology department of Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences A 65 yearold woman with medical history of . A Review of the 2013 ACC/AHA Cholesterol Guidelines. Timothy Gladwell, . Pharm.D. ., BCPS, BCACP. Associate Professor and Vice Chair. Department of Pharmacy Practice. Husson. University School of Pharmacy. . John Baer. What is it?. Hyperlipidemia. - any condition that elevates fasting blood triglyceride and cholesterol concentrations. Dyslipidemia. - altered blood lipid and lipoprotein concentrations. Michael Hunt, . Director, Health Spending and Strategic Initiatives. Canadian Institute for Health Information (CIHI). Shari . Dworkin. , Director, Canada Health . Infoway. SCWG Concurrent Session. November 26, 2013 8.30am. 2013 ACC/AHA Guideline on the. Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. IMPROVE-IT. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia. MAHTAB NIROOMAND M.D.. Assistant professor of Endocrinology. SBUMS. Tehran 1391/11/19. . Out-line . Pathophysiology. and types of dyslipidemia in diabetic patients. Benefits of lipid- lowering therapy. What is it?. Hyperlipidemia. - any condition that elevates fasting blood triglyceride and cholesterol concentrations. Dyslipidemia. - altered blood lipid and lipoprotein concentrations. Hypercholesterolemia- elevated cholesterol. atherogenic. role of CETP and future use of CETP inhibitors. Prof. John Betteridge. University College London. United Kingdom. Diabetes and Cardiovascular Disease: Time To Act!. “With the rising tide of diabetes around the globe, the double jeopardy of diabetes and cardiovascular disease is set to result in an explosion of these and other complications- unless preventive action is taken.”. This is a thick, hard deposit that can narrow the arteries and make them less flexible. This condition is known as atherosclerosis. As the artery narrows and hardens, less blood can get through causin Clinics (www.dhs.state.mn.us) ProcedureRisk AssessmentThe following are examples of recommended risk factors that can be identified through the personal and family health history and physical measurem VA/DoD Clinical Practice Guideline Introduction Page Prepared by: THE MANAGEMENT OF DYSLIPIDEMIA The Office of Quality and PerfQuality Management Directorate,Version 1.0 – 1999 Updated Version , MD, FRCPC, FACP, CCD, ECNU.. Asst. Professor and Consultant . Medicine, Endocrinology. Department of Medicine, King Saud University. Lipid Transport. LPL/Apo C2. Rader DJ, Daugherty, A Nature 2008; 451:904-913 . , MD, FRCPC, FACP, CCD, ECNU.. Associate . Professor and Consultant . Medicine, Endocrinology. Department of Medicine, King Saud University. Lipid Transport. LPL/Apo C2. Rader DJ, Daugherty, A Nature 2008; 451:904-913 . Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella . D’Arminio. Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric . Lipidology. and Atherosclerosis (KSLA). . Hyper-LDL-. cholesterolemia. . LDL-cholesterol (LDL-. C. ) . ≥160 mg/. dL. . . or . use of lipid-lowering medication .